EAN 2023 Highlights Podcast

In this episode (19:10), Medicom’s correspondent covers 6 presentations from the annual meeting of the European Academy of Neurology Congress (EAN 2023), held in Budapest, Hungary, from 1-4 July 2023.
The topics discussed are:

1. EAN guidelines on the management of ALS
   New guidelines on the management of amyotrophic lateral sclerosis (ALS) were presented at the EAN 2023 meeting and are projected to be published before the end of 2023. The guidelines are a joint effort of the EAN in collaboration with ERN Euro-NMD. Three new drugs soon to be evaluated may necessitate an update of these guidelines soon.
2. Sleep changes contribute to the pathogenesis of neurodegenerative diseases
   The results of an Austrian study support the assumption that sleep changes contribute to the pathogenesis of neurodegenerative diseases (NDDs). Altered sleep architecture at baseline with reduced sleep efficiency, REM sleep or N3 sleep, or increased wake periods in sleep period time (SPT) was robustly associated with incident neurodegeneration after 5 years and more.
3. Cannabis-based medicine does not beat placebo in central neuropathic pain
   In a Danish multi-centre study, cannabis-based medicine (CBM) did not prove to be more effective than placebo in the treatment of central neuropathic pain (CP) during 7 weeks of treatment. Expectations for CBM were high, as was the placebo effect in this study.
4. Minimising co-medication optimises cenobamate efficacy in epilepsy
   A specialised neurology clinic in Seville, Spain, shared their successful efforts to optimise the efficacy of cenobamate in highly refractory focal epilepsy. By rapid and drastic reduction of co-medication, higher mean cenobamate doses and very high seizure reduction rates could be reached.
5. GLP-1 agonists induce weight loss and alleviate headache in idiopathic intracranial hypertension
   In patients with idiopathic intracranial hypertension (IIH), GLP-1 agonists were found to be a safe and effective treatment option for achieving significant weight loss. The therapy was also associated with favourable headache outcomes, possibly through an indirect effect of weight loss as well as a direct effect on intracranial pressure.
6. Intensive BP reduction associated with smaller haematoma
   Early use of intensive blood pressure (BP) reduction may reduce haematoma growth and improve outcome in patients with fast-bleeding, spontaneous intracerebral haemorrhage (ICH). This was concluded from an exploratory analysis of data from the ATACH-2 randomised-controlled trial.

Enjoy listening!

Copyright ©2023 Medicom Medical Publishers



Posted on 18 July 202327 June 2024